Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.
This article is a review of cyclic nucleotide phosphodiesterase(s) (CN PDE) from the point of view of the relationships between the newer aspects of the complex enzymology of CN PDE and recent major advances in CN PDE pharmacology. A consolidation of isozyme nomenclature to the proposed family designations is recommended. Emphasis is placed on the importance of defining the subcellular localization of isozymes expressed in a given tissue and cyclic GMP substrate and regulatory roles in CN PDE isozyme functions. CN PDE inhibitors that may be useful for experimental and clinical purposes are discussed. Examples of these inhibitors include CGS 9343B, TCV-3B, KW-6, MIMAX, Dihydroisoquinolines, Trequinsin, bipyridine and dihydropyridazinone cardiotonics, Rolipram, SQ 65442, Zaprinast and Dipyridamole.
Thompson
W J
WJ
Department of Pharmacology, University of South Alabama College of Medicine, Mobile.
D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000187:drug effects / Q000502:physiology*; D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D007527:Isoenzymes / Q000187:drug effects / Q000502:physiology*; D008969:Molecular Sequence Data; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D012689:Sequence Homology, Nucleic Acid
D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases